Literature DB >> 9028315

Roles of the N and C terminal domains of the interleukin-3 receptor alpha chain in receptor function.

S C Barry1, E Korpelainen, Q Sun, F C Stomski, P A Moretti, H Wakao, R J D'Andrea, M A Vadas, A F Lopez, G J Goodall.   

Abstract

The interleukin-3 (IL-3), granulocyte-macrophage colony-stimulating factor, and IL-5 receptor alpha chains are each composed of three extracellular domains, a transmembrane domain and a short intracellular region. Domains 2 and 3 constitute the cytokine receptor module (CRM), typical of the cytokine receptor superfamily; however, the function of the N-terminal domain is not known. We have investigated the functions of the N-terminal and C-terminal domains of the IL-3 receptor (IL-3R) alpha chain. We find that cells transfected with the receptor beta chain (h beta c) and a truncated IL-3R alpha that is devoid of the intracellular region fail to proliferate or to activate STAT5 in response to human IL-3, despite binding the IL-3 with affinity indistinguishable from that of full-length receptor. In addition, IL-3-induced phosphorylation of h beta c was not detected. Thus, the IL-3R alpha intracellular region does not contribute detectably to stabilization of the receptor/ligand complex, but is essential for signal propagation. In contrast, a truncated IL-3R alpha with the N-terminal domain deleted interacts functionally with the beta chain; mouse cells transfected with these receptor chains proliferate in response to human IL-3 and STAT5 transcription factor is activated. High- and low-affinity binding sites are retained, although the affinity for IL-3 is decreased 15-fold, indicating a significant role for the N-terminal domain in IL-3 binding.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9028315

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  6 in total

Review 1.  Role of the β Common (βc) Family of Cytokines in Health and Disease.

Authors:  Timothy R Hercus; Winnie L T Kan; Sophie E Broughton; Denis Tvorogov; Hayley S Ramshaw; Jarrod J Sandow; Tracy L Nero; Urmi Dhagat; Emma J Thompson; Karen S Cheung Tung Shing; Duncan R McKenzie; Nicholas J Wilson; Catherine M Owczarek; Gino Vairo; Andrew D Nash; Vinay Tergaonkar; Timothy Hughes; Paul G Ekert; Michael S Samuel; Claudine S Bonder; Michele A Grimbaldeston; Michael W Parker; Angel F Lopez
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

2.  High CD123 levels enhance proliferation in response to IL-3, but reduce chemotaxis by downregulating CXCR4 expression.

Authors:  Nicole L Wittwer; Gabriela Brumatti; Ceilidh Marchant; Jarrod J Sandow; Melanie K Pudney; Mara Dottore; Richard J D'Andrea; Angel F Lopez; Paul G Ekert; Hayley S Ramshaw
Journal:  Blood Adv       Date:  2017-06-20

3.  Plasmacytoid dendritic cells appear inactive during sub-microscopic Plasmodium falciparum blood-stage infection, yet retain their ability to respond to TLR stimulation.

Authors:  Jessica R Loughland; Gabriela Minigo; Derek S Sarovich; Matt Field; Peta E Tipping; Marcela Montes de Oca; Kim A Piera; Fiona H Amante; Bridget E Barber; Matthew J Grigg; Timothy William; Michael F Good; Denise L Doolan; Christian R Engwerda; Nicholas M Anstey; James S McCarthy; Tonia Woodberry
Journal:  Sci Rep       Date:  2017-06-01       Impact factor: 4.379

Review 4.  Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats.

Authors:  Brent A Williams; Arjun Law; Judit Hunyadkurti; Stephanie Desilets; Jeffrey V Leyton; Armand Keating
Journal:  J Clin Med       Date:  2019-08-20       Impact factor: 4.241

5.  MARCH3 negatively regulates IL-3-triggered inflammatory response by mediating K48-linked polyubiquitination and degradation of IL-3Rα.

Authors:  Lu Feng; Chen Li; Lin-Wen Zeng; Deng Gao; Yu-Hao Sun; Li Zhong; Heng Lin; Hong-Bing Shu; Shu Li
Journal:  Signal Transduct Target Ther       Date:  2022-01-24

6.  CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies.

Authors:  Ugo Testa; Elvira Pelosi; Arthur Frankel
Journal:  Biomark Res       Date:  2014-02-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.